YOLFTbeta
TaiRx, Inc.

TaiRx, Inc.

6580 · TWO · Healthcare / Biotechnology

10.55TWD+0.05 (+0.48%)

Price History

Full chart

Market Stats

Previous Close10.50
Open10.50
Day Range10.25 – 10.60
52-Week Range11.95 – 27.60
Volume60.71K
Market Cap1.74B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.09
Dividend Yield0.00%
Beta0.37
50-Day Avg13.55
200-Day Avg16.23

About

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Du-Shieng Chien Ph.D.
  • HeadquartersNo. 66, San-Chung Road, Taipei, Taiwan, 115602, Taiwan
  • Websitehttps://www.trx.com.tw

Leadership

  • Dr. Du-Shieng Chien Ph.D.Co-Founder, President, CEO & Director
  • Dr. Yi-Wen Chu Ph.D.Senior VP & Director
  • Mr. Huang Shiqi M.A.CFO & Accounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.16M3.36M5.14M6.92M5.08M8.22M27.88M
Growth (%)-+6.43%+53.05%+34.66%-26.59%+61.79%+239.03%
Cost of Revenue1.65M1.76M2.69M2.97M2.64M6.88M17.79M
Gross Profit1.50M1.60M2.45M3.95M2.44M1.34M10.09M
Gross Margin47.62%47.63%47.62%57.09%47.99%16.33%36.19%
Operating Expense164.75M164.62M132.63M217.03M217.13M147.31M247.44M
Operating Income-163.25M-163.02M-130.18M-213.08M-214.69M-145.96M-237.36M
Operating Margin-5172.56%-4853.29%-2532.23%-3077.89%-4224.62%-1775.29%-851.50%
EBITDA-215.80M-157.78M-122.98M-207.18M-208.65M-131.25M-214.34M
EBITDA Margin-6837.80%-4697.29%-2392.16%-2992.62%-4105.59%-1596.27%-768.93%
Net Income-217.76M-159.39M-125.61M-211.58M-212.29M-138.84M-221.13M
Net Income Margin-6900.03%-4745.04%-2443.36%-3056.15%-4177.33%-1688.58%-793.28%
R&D178.83M118.73M84.46M168.46M173.08M102.77M175.50M
R&D as % of Total Revenue5666.29%3534.56%1642.79%2433.35%3405.80%1249.98%629.59%
Interest Expense619.00K190.00K146.00K172.00K332.00K275.00K167.00K
Interest Expense % of Total Revenue19.61%5.66%2.84%2.48%6.53%3.34%0.60%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets489.34M837.30M706.62M534.04M833.75M684.78M465.24M
Total Liabilities31.76M39.35M30.76M54.92M60.63M36.27M23.64M
Total Equity451.25M788.71M674.56M477.79M771.80M647.17M441.59M
Cash51.32M91.43M34.00M34.90M160.16M113.98M136.25M
Total Debt8.76M5.60M2.42M15.45M12.29M10.43M-
Net Debt-42.56M-85.83M-31.57M-19.45M-147.87M-103.55M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-168.87M-141.97M-124.41M-185.66M-194.88M-149.81M-178.47M
Investing Cash Flow100.42M-308.70M71.05M186.95M-176.74M99.67M-
Financing Cash Flow-33.68M490.85M-3.71M-409.00K496.90M3.87M-
Capital Expenditure0401.00K946.00K317.00K313.00K321.00K1.15M
Free Cash Flow-168.87M-142.37M-125.35M-185.98M-195.20M-150.13M-179.62M
FCF to OCF100.00%100.28%100.76%100.17%100.16%100.21%100.64%

Key Statistics & Ratios

Market Cap1.74B
Enterprise Value1.35B
Trailing P/E0.00
Forward P/E0.00
Price / Sales59.21
Price / Book4.44
EPS-2.09
Book Value3.27
Revenue (TTM)29.44M
Gross Profit (TTM)15.64M
EBITDA-243.95M
Profit Margin0.00%
Operating Margin-965.87%
Return on Equity-49.47%
Return on Assets-30.58%
Shares Outstanding112.12M
Shares Float87.28M
Beta0.37
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 14, 2019850:1000